Medpace Holdings (MEDP) logo

Medpace Holdings (MEDP) stock

Clinical trial services , market cap $18B

After-hours Fri
$605.49
-0.83%

Close $610.54 -3.70%

Quality Score
9
Average
In its industry
#31of 273
Checks firing
1of 14
Trending up
From 52-week high
-12.0%
under its best in a year

MEDP's Quality Score fell 2 points on Fri, Nov 20, to 9. Its week-by-week trend stopped pointing up (2 chart checks stopped).

See MEDP's 14 chart checksSee MEDP's 14 chart checksSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why MEDP beats the market

Up 177% over five years while the S&P 500 rose 58%; up 4% in the past year.

  • Its profit per share went from $3.84 to $15.28; revenue grew 22.3% a year.

Sources: Price history, Nov 20, 2026; Annual reports, Dec 31, 2025

1 more reason, free with an account →See every reason on MEDP →4 more reasons why MEDP beats the market, from its filings, with the timeline, for Pro members.

Key facts on MEDP

Key facts on MEDP
The chartStronger than 87% of stocks above a rising 200-day average
Latest filing10-Q, Oct 22 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

MEDP catalysts

Coming up

After its last 4 reports it closed -6.3% on average, higher 1 of 4 times.

31 past catalysts since 2018, with sizes and sources, for Pro members.

Why MEDP scores 9

Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

Well below its recent run. MEDP scores 9 today, against a median of 14 over its last 20 recorded sessions.

  • +3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high
  • −1Insider trades Susan E. Burwig (Exec. VP, Operations) sold $2.7M on Oct 27 near the 52-⁠week high. $147.2M sold by 4 sellers in three months
  • Chart checks adds
  • Run-up adds
  • Size adds
  • Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Persistence adds

No effect today: Dilution, Volatility, Cash flow, and News.

What every line is worth, and the reason behind it, on MEDP and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:34 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when MEDP's Quality Score turns up

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

How MEDP ranks in Biotech

MEDP is #31 of 273 by Quality Score.

How MEDP ranks in Biotech
RankStockQuality Score
31Medpace Holdings (MEDP) logoMEDPMedpace9

Sales over four quarters against a year before: MEDP +20%, ICLR +0.4%, IQV +8.8%.

More in Biotech

When does MEDP report earnings, and what happens after?

Expected to report Mon Feb 8, after the close (in 79 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What MEDP reported on Oct 21, 2026

The quarter

Sales of $716.0M, 9% more than a year ago; a profit of $4.84 a share, from $3.86.

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By product
Oncologyup 19%$230M32%$209M30%$193M29%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 22)

5 more lines, for Pro members.

The outlook

The outlook the company gave, by period
MeasureFigure
Full year 2026
Diluted earnings per share (GAAP)$17.97 to $18.32raised

Figures as filed (SEC filing, Oct 21)

4 more outlook lines, for Pro members.

The numbers

Market value
$18B
today
Sales
$2.8B
up 20.4% on the year
Free cash flow
$668M
last 12 months

Sales grew 22% a year over 5 years, fiscal 2020 to 2025.

Its share count fell 4.8% a year over 5 years.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on MEDP: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-22.6%+14.7%-1.3%
Apr 22Jul 22Oct 21
ReportedGapReaction5
days
Oct 21, 2026After close-0.8%-1.3%+4.6%
Jul 22, 2026After close+22.5%+14.7%+10.8%
Apr 22, 2026After close-26.2%-22.6%-18.7%

MEDP closed higher after 1 of its last 4 reports.

All 4 reports, and MEDP's Quality Score going into each

MEDP sales and profit by year

Sales and profit by year

Sales grew every year from 2018 to 2025, to $2.5B. It made a profit in each of the eight years.

MEDP has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on MEDP, and all 14 on every stock.Get in free →See the top 3 →Start Pro

MEDP RSI on Nov 20: 37.9, below its 50-day, above its 200-day

Not scored

RSI 37.9, MACD below signal, below its 50-day, above its 200-day. Not scored.

The deep dive on MEDP

7 more findings on MEDP, each with its source, for Pro members.

MEDP insider trades

8 insiders sold $230M across 35 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellStephen P. Ewald$859KGeneral Counsel & Corp. Secy.at $690.00 on Oct 29, filed Nov 2

All 35 insider filings on MEDP from the last six months, for Pro members.

All MEDP insider trades

MEDP trades by Congress and the executive branch

One trade disclosed in the last six months. The newest:

BuyDavid Taylor$1K to $15KHousetraded May 15, disclosed May 28(13 days later)

See what Congress is buying across the market

MEDP's officers and directors

Officers and directors with a Form 4 in the last 12 months.

One more officer or director files at MEDP.

See insider trades by person

Which ETFs hold MEDP?

In ETFs: MEDP is under 0.1% of SCHG and under 0.1% of VTI, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.

About Medpace Holdings

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

6,600 employeesCincinnati, OHmedpace.com

What Medpace Holdings says it competes with

“We compete primarily against other full-service CROs as well as services provided by in-house research and development (R&D) departments of biopharmaceutical companies.”

From its annual report, SEC filing · Feb 10, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on MEDP and every other stock.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would move MEDP's score: 5 things
  • 2 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayMay 28David Taylor bought MEDP$1K to $15K, disclosed May 28

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: MEDP's Quality Score is 9 (Average), #31 of 273 in Biotech. Insiders sold $230M in the last 6 months (Form 4).

What does MEDP's Quality Score say?

MEDP scores 9 today, which Breakaway calls Average. It is #31 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Up 177% over five years while the S&P 500 rose 58%; up 4% in the past year. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is MEDP's Quality Score?

MEDP scores 9 today, which Breakaway calls Average (6 to 10). That is #31 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MEDP's 9.

Are insiders buying MEDP?

8 insiders sold $230M across 35 filings in the last 6 months. No open-⁠market buys on record. The newest is Stephen P. Ewald, General Counsel & Corp. Secy., who sold $859K on Oct 29. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.